Robert Giovanni Nisticò, who is the new president of AIFA
Close to Forza Italia for family issues and to the Minister of Health, Orazio Schillaci, for academic reasons, Robert Giovanni Nisticò has been appointed new president of the (reformed) AIFA, a position that is rumored to have been rejected by many also due to the salary… All the details
Robert Giovanni Nisticò will lead the Italian Medicines Agency (Aifa) for the next 5 years. A month and a half after the surprise resignation of the virologist Giorgio Palù, the conferences of the Regions, State-Regions and Unified have given a favorable opinion to the proposal of the Minister of Health, Orazio Schillaci.
The appointment is part of a renewed context after the government started the reform of the Agency at the end of November 2023 which, having abolished the role of the general director , places all powers in the hands of the president.
WHO IS THE NEW PRESIDENT OF AIFA
Born in 1974, born in London but raised in Italy, Robert Giovanni Nisticò is the son of the pharmacologist Giuseppe known as Pino, former undersecretary of Health in the first Berlusconi government, president of the Calabria region from 1995 to 1998 and member of the European Parliament.
He graduated in Medicine and Surgery at the Catholic University of Rome with a specialization in Psychiatry and Clinical Psychology achieved at the same university.
“Nisticò – writes Milano Finanza – is considered close to Forza Italia for family reasons and for academic reasons close to Minister Schillaci, former rector of the Tor Vergata university from which he also comes”. However, the nomination did not lack the support of the League through the blessing of the Minister of Economy Giancarlo Giorgetti and of the Conference of Regions led by the president of the Friuli-Venezia-Giulia region Massimiliano Fedriga.
THE ACADEMIC CAREER
Nisticò was first a researcher and then an associate professor of Pharmacology at the Faculty of Pharmacy of the University of Calabria. He was an extraordinary professor at the Faculty of Pharmacy and Medicine of the University of Rome La Sapienza and since 2015 he has been an associate professor of Pharmacology at the Department of Biology of the University of Rome Tor Vergata, where he teaches general pharmacology and toxicology, neuropsychopharmacology.
At the University of Rome Tor Vergata he is also president of the single-cycle master's degree course in Pharmacy.
From his CV it can be seen that he is the author or co-author of over 129 publications in full (PubMed source) in indexed international journals, 10 book chapters and over 150 abstracts of communications at national and international conferences.
Since 2015 he has been principal investigator at the Ebri – European Brain Research Institute of the Rita-Levi Montalcini Foundation, in the Neuropharmacology Laboratory.
INSTITUTIONAL TASKS
Nisticò has added an institutional career to his academic career. Since January 2015 he has been a Regulatory Affairs expert at the Malta Medicines Agency, where he deals with scientific and regulatory evaluation in the context of centralized and decentralized procedures.
Among other international positions, those of Alternate Delegate at the European Innovative Medicines Initiative (IMI), since October 2015, and member of the Committee for Orphan Medicinal Products (Comp) of the European Medicines Agency (EMA), since September 2016.
HOW MUCH WILL YOU EARN
According to Milano Finanza, the position of president of AIFA, although prestigious, was "rejected by several potential candidates for a series of reasons". Among these, "a salary (120 thousand euros gross per year) not commensurate with the responsibilities of the role and above all almost half less than that of the closest collaborators, the administrative director and the technical-scientific director".
“An anomaly – adds the article – which will be amended in the coming weeks through an ad hoc decree, with which the ministries of Health and Economy will establish the president's new compensation, which could rise up to 190 thousand euros”.
WHAT AWAITS HIM
Nisticò will chair the five-member board of directors composed of Francesco Fera (who was acting after Palù's resignation), Emanuele Monti representing the Mef, and Vito Montanaro and Angelo Gratarola representing the regions. The new president, specifies MF , will have to "contribute to the management of pharmaceutical spending which in the first nine months of 2023 reached a total of 16.4 billion euros, an increase of 6.9% compared to the same period of the previous year" .
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/robert-giovanni-nistico-chi-e-il-nuovo-presidente-dellaifa/ on Thu, 04 Apr 2024 14:12:18 +0000.